Clinical Biopsy Articles & Analysis
23 news found
“The development and clinical validation of a potentially more sensitive and informative method for detecting minimal residual disease in patients with EBC may help facilitate a switch to a truly personalized clinical management of these patients, which may improve outcomes and reduce the risk of recurrence,“ says Dr. ...
About Carcinotech Carcinotech is revolutionising cancer research by manufacturing 3D-printed micro-tumours using patient-derived biopsies, primary cells, immune cells, and cancer stem cells. Our advanced offering provides a platform for rapid, ethical, and accurate drug screening, pre-clinical, and personalised medicine testing. Carcinotech’s goal is to ...
ByCELLINK
With this partnership, the companies will offer an optimized workflow for a wide range of applications including liquid biopsy, sentinel pathogen testing, infectious disease assays, overall cancer research and drug discovery. Representative data of the liquid biopsy workflow will be presented at the American Association for Cancer Research (AACR) Annual Meeting ...
The poster attracted interest from many potential companies in the clinical lab space on the use of this novel integrated technology for cancer screening application. Promising discussions with several clinical/lab operators have commenced. The Company also presented clinical validation data at the ESMO Congress 2022 that took place on ...
It combines the accuracy of MRI with the real-time monitoring of ultrasound to detect more clinically significant cancer, while preventing unnecessary biopsies. Unlike standard systematic biopsy, fusion can track lesions over time with imaging or repeat biopsy during active surveillance. ...
BioMark is currently pursuing two clinical trials using this liquid biopsy platform that can improve identification and assessing response to treatment for patients with lung cancer and glioblastoma. ...
Compared to standard systematic biopsies, MRI-targeted fusion biopsies improve the detection of clinically significant prostate cancer. ...
Key priorities in this development will be the completion of the clinical development programs that are already underway in liver and breast cancer and their regulatory approval, as well as thecompletion of the industrial scale-up in Europe and the US of the safe-biopsy device, which has already been clinically tested in lung and liver ...
Fin Posillipo (Petrone Group], Kairos Partners SGR, LIFTT, Neva Sgr (Intesa Sanpaoh Group), Profequycapital and Romedjoined the share capital Innogest Capital and Panakes Partners reinvest The financing will give BetaGlue Technologies the ability to further develop its advanced radiotherapy platform, BAT-90, and accelerate access to the Safe-Biopsy Device market, thus opening ...
“These data show that treatment with LUPKYNIS can help patients with lupus nephritis successfully achieve UPCR treatment targets as recommended by the European Alliance of Associations for Rheumatology and the European Renal Association - a high bar to achieve and clinically meaningful,” said Dr. Anders. “A treatment response meeting these proteinuria treatment ...
Use of LUPKYNIS was safe and well tolerated in patients for up to three years of treatment, with no new safety signals In AURORA 2, long-term treatment with LUPKYNIS led to a clinically relevant preservation of kidney function in LN patients A pooled analysis from the AURA-LV and AURORA 1 studies, also presented at ERA, showed early treatment response to LUPKYNIS with ...
The foundational LCD identifies evidence supporting the clinical utility of our SelectMDx test and, when the LCD becomes effective on July 3, 2022, is expected to support coverage of our test for qualified Medicare patients throughout the United States. Michael McGarrity, CEO of MDxHealth, commented: “We are pleased to report this very positive and important development ...
In partnering with Promaxo, we are bringing minimally invasive, office based MRI to Beverly Hills, California, with a clinical focus on MR guided biopsies and treatments such as high intensity focused ultrasound (HIFU) of the prostate ...
(Nasdaq: GH), a leading precision oncology company, today announced it will present data highlighting the clinical utility of its liquid biopsy tests in the treatment and management of early- to late-stage gastrointestinal cancers, including colorectal cancer, at the 2022 ASCO Gastrointestinal Cancers Symposium being held January 20-22, 2022. ...
“When used alongside the AI decision support tool, OA imaging has the potential to reduce false positives and thus biopsies of benign masses, versus ultrasound alone, without sacrificing sensitivity.” Breast biopsy procedures caused by false-positive diagnostic assessments in the United States cost the healthcare system more than $2 billion per ...
This urgent awareness team effort occurs while the pioneering cooperation continues, as Puerto Rico has for the past year conducted clinical studies for a prostate cancer liquid biopsy breakthrough test developed by miR Scientific. ...
Tethis’ development is particularly exiting because it’s an enabling technology, one of those that can accelerate the clinical adoption of liquid biopsy testing, both for early detection of cancer and for personalized patient management. ...
Exosome Diagnostics is the world leader in developing exosomal liquid biopsy-based diagnostic assays. The EPI test is a non-invasive, urine-based genomic test that helps inform the prostate biopsy decision. ...
The system is indicated for use by trained and qualified healthcare providers to evaluate palpable and non-palpable breast abnormalities in adult patients who are referred for diagnostic imaging breast work-up following clinical presentation or other imaging examinations such as screening mammography. ...
The publication demonstrates the cost effectiveness and economic utility of Cleveland Diagnostics’ IsoPSA test for the detection of clinically significant prostate cancer. The published analysis projected cost savings of the IsoPSA test based on previous clinical evidence of its effectiveness compared to a standard of care workup to guide the need for a ...